| 注册
首页|期刊导航|天津中医药|基于解离度控制的桑枝生物碱树脂分离工艺优化

基于解离度控制的桑枝生物碱树脂分离工艺优化

牛安松 刘志华 金毅群 朱向阳 刘玉玲

天津中医药2016,Vol.33Issue(10):619-623,5.
天津中医药2016,Vol.33Issue(10):619-623,5.DOI:10.11656/j.issn.1672-1519.2016.10.11

基于解离度控制的桑枝生物碱树脂分离工艺优化

Optimization the purification progress on mulberry alkaloids based on the dissociation constants

牛安松 1刘志华 2金毅群 1朱向阳 2刘玉玲3

作者信息

  • 1. 中国医学科学院药物研究所,天然药物活性物质与功能国家重点实验室,北京 100050
  • 2. 中国医学科学院药物研究所,药物传输技术及新型制剂北京重点实验室,北京 100050
  • 3. 北京五和博澳药业有限公司,北京 102600
  • 折叠

摘要

Abstract

Objective] To select optimum regenerating agent of ion-exchange resin and optimize purification of mulberry alkaloids based on the pKa of the alkaloids and the pI of amino acids. [Methods] The 732 resins were regenerated with hydrochloric acid and different pH buffer solution, respectively. The productions were determined by RP-HPLC with pre-column derivatization. This article calculated the leakage amount of alkaloids and amino acids the adsorbing amount. Meanwhile it also determined the peak ratio of alkaloids in products. [Results] Ultimately, the total amino acids leaked in a short time with the buffer solution at pH 4.6 as regenerating agent. However, both of the alkaloids and amino acids didn’t leak with hydrochloric acid as regenerating agent. The adsorption amount was increased from 1.84 to 2.23 mg/g with the buffer solution at pH 4.6 compared to pH 5.6. The relative peak ratio of the alkaloids in productions is 79.6%with the buffer solution at pH 5.6 as regenerating agent, and 23.6%with hydrochloric acid as regenerating agent. [Conclusion] Through adjusting the pH of resin separation and controlling the dissociation degree of the alkaloids and the amino acids, the purity of the production was improved with decreased adsorption of amino acids and increased selectivity of the resin.

关键词

桑枝生物碱/1-脱氧野尻霉素/阳离子交换树脂/解离常数/吸附选择性

Key words

mulberry alkaloids/1-deoxynojirimycin/cation exchange resin/dissociation constant/selective adsorption

分类

医药卫生

引用本文复制引用

牛安松,刘志华,金毅群,朱向阳,刘玉玲..基于解离度控制的桑枝生物碱树脂分离工艺优化[J].天津中医药,2016,33(10):619-623,5.

基金项目

“重大新药创制”国家科技重大专项(2013ZX09101-005);“重大新药创制”科技重大专项(2012ZX09309002-001-008);北京市科技计划“十病十药”研发(Z11100059011010)。 ()

天津中医药

OACSTPCD

1672-1519

访问量4
|
下载量0
段落导航相关论文